GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer based on Stanford research.

The T-Cell therapy developer, based on research at Baylor College of Medicine, has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Hyundai-backed industrial security drone developer Percepto secured funding in a USVP-led series A round that boosted its overall equity financing to nearly $28m.

Pixie Dust Technologies, which promotes university-derived technologies from Japan, has received $34.7m in a round that included KDDI, Kansai Electric Power, NEC, Toppan, Dai-ichi Life and Dentsu.

DoorDash is now valued at $12.6bn after securing funding in a series G round backed by SoftBank Vision Fund, taking its total funding to nearly $2bn.

The T-Cell therapy developer has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.

GV participated in a round that will enable the on-demand recruitment platform to accelerate its expansion across the US.

Online investment management service Wealthsimple secured $74.6m in an Allianz X-led round that also featured long-standing investor Power Financial.

UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.